On this page
VITAMIN D
ergocalciferol · Capsule
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Ergocalciferol | 1.25 mg/1 | 1367410 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Ergocalciferols [CS] | CS | All 12 members |
| Provitamin D2 Compound [EPC] | EPC | 4 members — no class page |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 090455-001 | ERGOCALCIFEROL | CAPSULE | ERGOCALCIFEROL | Prescription | AA | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | August 3, 2010 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251007). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. Vitamin D Resistant Rickets: 12,000 to 500,000 USP Units daily. Hypoparathyroidism: 50,000 to 200,000 USP Units daily concomitantly with calcium lactate 4 g, six times per day. DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION. Calcium intake should be adequate. Blood calcium and phosphorus determinations must be made every 2 weeks or more frequently if necessary. X-rays of the bones should be taken every month until condition is corrected and stabilized.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Ergocalciferol Capsules, USP are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.
Warnings
openFDA Drug LabelingWARNINGS Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia. In these cases vitamin D must be strictly restricted. Keep out of the reach of children.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Hypervitaminosis D is characterized by effects on the following organ system: Renal: Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. CNS: Mental retardation. Soft Tissues: Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Skeletal: Bone demineralization (osteoporosis) in adults occurs concomitantly. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism) vague aches, stiffness, and weakness. Gastrointestinal: Nausea, anorexia, constipation. Metabolic: Mild acidosis, anemia, weight loss. Call your doctor for medical advice about side effects. You may report side effects to Strides Pharma Inc. at 1-877-244-9825 or go to www.strides.com
Drug Interactions
openFDA Drug LabelingDrug Interactions Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations. Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with Ergocalciferol Capsules, USP may cause hypercalcemia.
Description
openFDA Drug LabelingDESCRIPTION Ergocalciferol Capsules, USP are a synthetic calcium regulator for oral administration. Ergocalciferol is a white, colorless crystal, insoluble in water, soluble in organic solvents, and slightly soluble in vegetable oils. It is affected by air and by light. Ergosterol or provitamin D 2 is found in plants and yeast and has no antirachitic activity. There are more than 10 substances belonging to a group of steroid compounds, classified as having vitamin D or antirachitic activity. One USP unit of vitamin D 2 is equivalent to one International Unit (IU), and 1 mcg of vitamin D 2 is equal to 40 USP Units. Each capsule contains Vitamin D (Ergocalciferol) 1.25 mg equivalent to 50,000 USP Units in an edible vegetable oil. Ergocalciferol, also called vitamin D 2 , is 9,10-secoergosta-5,7,10(19), 22-tetraen-3-ol, (3β,5Z,7E,22 E )-; (C 28 H 44 O) with a molecular weight of 396.65, and has the following structural formula: Inactive Ingredients: 2-Ethoxyethanol, FD&C Blue #1, FD&C Yellow #5, Gelatin, Glycerin, Lecithin, Medium chain triglyceride, Purified water, Shellac glaze (modified) IN SD-45, Simethicone, Soybean oil and Titanium dioxide. Vitamin D structure
Overdosage
openFDA Drug LabelingOVERDOSAGE The effects of administered vitamin D can persist for two or more months after cessation of treatment. Hypervitaminosis D is characterized by: 1. Hypercalcemia with anorexia, nausea, weakness, weight loss, vague aches and stiffness, constipation, mental retardation, anemia, and mild acidosis. 2. Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. 3. Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Bone demineralization (osteoporosis) in adults occurs concomitantly. 4. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism). The treatment of hypervitaminosis D with hypercalcemia consists in immediate withdrawal of the vitamin, a low calcium diet, generous intake of fluids, along with symptomatic and supportive treatment. Hypercalcemic crisis with dehydration, stupor, coma, and azotemia requires more vigorous treatment. The first step should be hydration of the patient. Intravenous saline may quickly and significantly increase urinary calcium excretion. A loop diuretic (furosemide or ethacrynic acid) may be given with the saline infusion to further increase renal calcium excretion. Other reported therapeutic measures include dialysis or the administration of citrates, sulfates, phosphates, corticosteroids, EDTA (ethylenediaminetetraacetic acid), and mithramycin via appropriate regimens. With appropriate therapy, recovery is the usual outcome when no permanent damage has occurred. Deaths via renal or cardiovascular failure have been reported. The LD 50 in animals is unknown. The toxic oral dose of ergocalciferol in the dog is 4 mg/kg.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Each capsule contains Vitamin D (Ergocalciferol) 1.25 mg equivalent to 50,000 USP Units. The green colored oval shaped transparent soft gelatin capsules are imprinted with '194' in white and contain clear light yellow oily liquid. Bottles of 06 capsules (NDC: 63187-519-06) Bottles of 08 capsules (NDC: 63187-519-08) Bottles of 12 capsules (NDC: 63187-519-12) Bottles of 16 capsules (NDC: 63187-519-16) Bottles of 30 capsules (NDC: 63187-519-30) Bottles of 60 capsules (NDC: 63187-519-60) Bottles of 90 capsules (NDC: 63187-519-90) Store at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light. Manufactured By: Strides Pharma Science Ltd. Bengaluru - 562106, India. Distributed By: Strides Pharma Inc 201 South Main Street, Suite 3 Lambertville, NJ 08530 USA (06-2014) Repackaged By: Proficient Rx LP Thousand Oaks, CA 91320
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: ERGOCALCIFEROL. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 71610-552-03 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 3 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-03) | June 20, 2024 |
| 71610-552-04 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 4 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-04) | May 4, 2021 |
| 71610-552-06 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 6 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-06) | June 16, 2026 |
| 71610-552-08 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 8 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-08) | November 12, 2024 |
| 71610-552-09 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 9 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-09) | June 16, 2026 |
| 71610-552-12 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 12 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-12) | May 4, 2021 |
| 71610-552-13 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 13 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-13) | August 25, 2023 |
| 71610-552-25 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 25 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-25) | June 16, 2026 |
| 71610-552-47 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 24 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-47) | November 19, 2025 |
| 71610-552-49 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 5 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-49) | June 16, 2026 |
| 71610-552-68 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | 26 CAPSULE in 1 BOTTLE, PLASTIC (71610-552-68) | November 19, 2025 |
| 50268-297-15 | 50268-297 | AvPAK | 50 BLISTER PACK in 1 BOX (50268-297-15) / 1 CAPSULE in 1 BLISTER PACK (50268-297-11) | April 7, 2020 |
| 71335-0278-0 | 71335-0278 | Bryant Ranch Prepack | 45 CAPSULE in 1 BOTTLE (71335-0278-0) | March 18, 2015 |
| 71335-0278-1 | 71335-0278 | Bryant Ranch Prepack | 12 CAPSULE in 1 BOTTLE (71335-0278-1) | March 18, 2015 |
| 71335-0278-2 | 71335-0278 | Bryant Ranch Prepack | 30 CAPSULE in 1 BOTTLE (71335-0278-2) | March 18, 2015 |
| 71335-0278-3 | 71335-0278 | Bryant Ranch Prepack | 100 CAPSULE in 1 BOTTLE (71335-0278-3) | March 18, 2015 |
| 71335-0278-4 | 71335-0278 | Bryant Ranch Prepack | 4 CAPSULE in 1 BOTTLE (71335-0278-4) | March 18, 2015 |
| 71335-0278-5 | 71335-0278 | Bryant Ranch Prepack | 20 CAPSULE in 1 BOTTLE (71335-0278-5) | March 18, 2015 |
| 71335-0278-6 | 71335-0278 | Bryant Ranch Prepack | 8 CAPSULE in 1 BOTTLE (71335-0278-6) | March 18, 2015 |
| 71335-0278-7 | 71335-0278 | Bryant Ranch Prepack | 15 CAPSULE in 1 BOTTLE (71335-0278-7) | March 18, 2015 |
| 71335-0278-8 | 71335-0278 | Bryant Ranch Prepack | 120 CAPSULE in 1 BOTTLE (71335-0278-8) | March 18, 2015 |
| 71335-0278-9 | 71335-0278 | Bryant Ranch Prepack | 60 CAPSULE in 1 BOTTLE (71335-0278-9) | March 18, 2015 |
| 51407-700-01 | 51407-700 | Golden State Medical Supply, Inc. | 100 CAPSULE in 1 BOTTLE, PLASTIC (51407-700-01) | October 11, 2024 |
| 51655-774-27 | 51655-774 | Northwind Health Company, LLC | 12 CAPSULE in 1 BOTTLE, PLASTIC (51655-774-27) | September 21, 2022 |
| 51655-774-52 | 51655-774 | Northwind Health Company, LLC | 30 CAPSULE in 1 BOTTLE, PLASTIC (51655-774-52) | January 27, 2023 |
| 51655-774-80 | 51655-774 | Northwind Health Company, LLC | 8 CAPSULE in 1 BOTTLE, PLASTIC (51655-774-80) | August 29, 2022 |
| 72789-249-01 | 72789-249 | PD-Rx Pharmaceuticals, Inc. | 100 CAPSULE in 1 BOTTLE, PLASTIC (72789-249-01) | May 5, 2022 |
| 72789-249-12 | 72789-249 | PD-Rx Pharmaceuticals, Inc. | 12 CAPSULE in 1 BOTTLE, PLASTIC (72789-249-12) | May 5, 2022 |
| 72789-249-13 | 72789-249 | PD-Rx Pharmaceuticals, Inc. | 13 CAPSULE in 1 BOTTLE, PLASTIC (72789-249-13) | May 5, 2022 |
| 68788-7627-1 | 68788-7627 | Preferred Pharmaceuticals, Inc. | 100 CAPSULE in 1 BOTTLE, PLASTIC (68788-7627-1) | June 1, 2020 |
| 68788-7627-2 | 68788-7627 | Preferred Pharmaceuticals, Inc. | 12 CAPSULE in 1 BOTTLE, PLASTIC (68788-7627-2) | June 1, 2020 |
| 68788-7627-3 | 68788-7627 | Preferred Pharmaceuticals, Inc. | 30 CAPSULE in 1 BOTTLE, PLASTIC (68788-7627-3) | June 1, 2020 |
| 68788-7627-8 | 68788-7627 | Preferred Pharmaceuticals, Inc. | 8 CAPSULE in 1 BOTTLE, PLASTIC (68788-7627-8) | June 1, 2020 |
| 63187-519-06 | 63187-519 | Proficient Rx LP | 6 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-06) | October 2, 2017 |
| 63187-519-08 | 63187-519 | Proficient Rx LP | 8 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-08) | January 1, 2016 |
| 63187-519-12 | 63187-519 | Proficient Rx LP | 12 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-12) | October 28, 2020 |
| 63187-519-16 | 63187-519 | Proficient Rx LP | 16 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-16) | February 1, 2016 |
| 63187-519-30 | 63187-519 | Proficient Rx LP | 30 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-30) | August 3, 2015 |
| 63187-519-60 | 63187-519 | Proficient Rx LP | 60 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-60) | August 3, 2015 |
| 63187-519-90 | 63187-519 | Proficient Rx LP | 90 CAPSULE in 1 BOTTLE, PLASTIC (63187-519-90) | August 3, 2015 |
| 70518-1878-1 | 70518-1878 | REMEDYREPACK INC. | 12 CAPSULE in 1 BOTTLE, PLASTIC (70518-1878-1) | August 28, 2019 |
| 64380-737-06 | 64380-737 | Strides Pharma Science Limited | 100 CAPSULE in 1 BOTTLE, PLASTIC (64380-737-06) | May 16, 2014 |
| 64380-737-25 | 64380-737 | Strides Pharma Science Limited | 50 CAPSULE in 1 BOTTLE, PLASTIC (64380-737-25) | May 16, 2014 |
| 71610-552 | 71610-552 | Aphena Pharma Solutions - Tennessee, LLC | — | May 16, 2014 |
| 50268-297 | 50268-297 | AvPAK | — | April 7, 2020 |
| 71335-0278 | 71335-0278 | Bryant Ranch Prepack | — | May 16, 2014 |
| 51407-700 | 51407-700 | Golden State Medical Supply, Inc. | — | August 3, 2010 |
| 51655-774 | 51655-774 | Northwind Health Company, LLC | — | August 29, 2022 |
| 72789-249 | 72789-249 | PD-Rx Pharmaceuticals, Inc. | — | May 16, 2014 |
| 68788-7627 | 68788-7627 | Preferred Pharmaceuticals, Inc. | — | June 1, 2020 |
| 63187-519 | 63187-519 | Proficient Rx LP | — | May 16, 2014 |
| 70518-1878 | 70518-1878 | REMEDYREPACK INC. | — | February 18, 2019 |
| 64380-737 | 64380-737 | Strides Pharma Science Limited | — | May 16, 2014 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.